Hematocrit: What Your Number Changes About Your Treatment

What Hematocrit Actually Measures

Hematocrit is the fraction of whole blood composed of red blood cells, expressed as a percentage. A reading of 45% means red blood cells occupy 45 out of every 100 units of blood volume, with the remaining 55% made up of plasma, white blood cells, and platelets. The test requires a standard venous blood draw processed through a complete blood count (CBC) panel.

Red blood cells carry oxygen from the lungs to every tissue in the body. When their proportion increases beyond normal limits, blood viscosity rises. Thicker blood moves more slowly through capillaries and small vessels, increasing shear stress on vessel walls and raising the probability of thromboembolic events 1. This is the reason hematocrit sits at the center of testosterone therapy safety monitoring.

The test is inexpensive. Most commercial labs include it in a basic CBC, which typically costs between $10 and $30 without insurance. Results are available within hours. Unlike free testosterone or estradiol assays, which require specific timing and methodology, hematocrit is straightforward to measure with minimal inter-lab variability 2.

One common source of confusion: hematocrit and hemoglobin are not the same test. Hemoglobin measures the oxygen-carrying protein inside red blood cells in grams per deciliter. Hematocrit measures the physical volume those cells occupy. The two values correlate closely (hematocrit is roughly three times the hemoglobin value), but clinicians use hematocrit as the primary safety trigger for testosterone therapy decisions because it more directly reflects blood viscosity 3.

Normal Hematocrit Ranges and What Shifts Them

For adult men, the standard reference range falls between 38.3% and 48.6%. For adult women, the range is 35.5% to 44.9%. These numbers come from sea-level populations, and the range shifts with altitude, hydration status, and age 4.

Altitude matters more than most patients realize. Living above 1,500 meters stimulates erythropoietin (EPO) production in the kidneys, which drives red blood cell synthesis. A man in Denver with a baseline hematocrit of 50% is not necessarily polycythemic. His body is compensating for lower atmospheric oxygen partial pressure. The Endocrine Society acknowledges altitude-adjusted baselines but does not publish separate TRT thresholds for high-altitude populations 5.

Dehydration is the most frequent cause of a falsely elevated reading. Plasma volume contracts when fluid intake drops, concentrating the cellular elements. A patient who fasts overnight and skips water before a morning blood draw can see hematocrit climb 2 to 4 points above their true steady-state value. Clinicians should confirm an elevated reading with a repeat draw after adequate hydration before making dosing changes 6.

Age plays a role too. Men over 70 often show a gradual decline in hematocrit as testosterone production falls and bone marrow activity slows. Women see hematocrit rise after menopause as monthly blood loss ceases, with average values climbing roughly 1 to 2 percentage points within the first two postmenopausal years 7.

Other factors that shift hematocrit include obstructive sleep apnea (chronic intermittent hypoxia stimulates EPO), chronic kidney disease (impaired EPO production lowers it), smoking (carboxyhemoglobin triggers compensatory erythropoiesis), and iron status.

How Testosterone Therapy Raises Hematocrit

Testosterone stimulates erythropoiesis through two mechanisms: direct stimulation of erythroid progenitor cells in bone marrow, and suppression of hepcidin, the liver peptide that restricts iron absorption. The net effect is more red blood cells produced faster, with more iron available to fill them 8.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older, found that testosterone gel raised hematocrit by a mean of 2.6 percentage points over 12 months compared to placebo 9. Injectable testosterone cypionate tends to produce larger spikes. A 2014 pharmacokinetic analysis of 200 mg intramuscular testosterone cypionate every two weeks showed peak-to-trough hematocrit variation of up to 4 percentage points within a single injection cycle 10.

The 2018 Endocrine Society Clinical Practice Guideline states: "We recommend against testosterone therapy in men who have hematocrit above 48% at baseline until the cause is identified. We recommend checking hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit rises above 54%, stop testosterone therapy until hematocrit decreases to a safe level" 5. That 54% threshold is the single most important number in TRT safety monitoring.

Not every man on testosterone crosses that line. A retrospective cohort study of 3,422 hypogonadal men on TRT published in the Journal of Clinical Endocrinology & Metabolism found that 11.2% developed hematocrit values above 54% during the first year of therapy 11. Risk factors for crossing the threshold included baseline hematocrit above 44%, intramuscular (versus transdermal) delivery, doses producing supraphysiologic trough levels, concurrent sleep apnea, and smoking.

What Happens When Hematocrit Gets Too High

Polycythemia (hematocrit above 48% in men, above 44% in women, with secondary polycythemia specifically referring to elevations driven by EPO or exogenous androgens) increases cardiovascular risk through elevated blood viscosity. Thicker blood requires greater cardiac effort to circulate, raises peripheral resistance, and promotes platelet aggregation at sites of endothelial disruption.

The clinical consequences are not theoretical. A 2019 meta-analysis of 15 observational studies covering 109,524 men found that hematocrit above 50% was associated with a 1.5-fold increase in major adverse cardiovascular events, including myocardial infarction and stroke, compared to men with hematocrit between 40% and 45% 12. The risk curve is not linear. It steepens sharply above 52%.

Dr. Shalender Bhasin, professor of medicine at Harvard Medical School and lead author of the Endocrine Society testosterone guideline, has stated: "The 54% threshold was chosen because the risk of thrombotic events increases substantially above this level, and it provides a margin of safety for patients on testosterone replacement" 5.

Symptoms of elevated hematocrit include headaches, dizziness, flushed skin, visual disturbances, and fatigue (paradoxically, because poor microcirculation limits oxygen delivery despite an excess of oxygen-carrying cells). Many patients report no symptoms at all. This is why lab monitoring is non-negotiable; you cannot feel a hematocrit of 53% versus 47%.

Protocol Changes Triggered by High Hematocrit

When hematocrit rises above 54%, the treatment algorithm follows a defined sequence. The first step is always to confirm the reading with a repeat CBC after ensuring the patient is well-hydrated. Dehydration-corrected values that remain above 54% require action.

Dose reduction. The most common first intervention is lowering the testosterone dose by 20% to 30% and rechecking hematocrit in 4 to 6 weeks. Switching from intramuscular injections to transdermal gel or a nasal formulation reduces peak androgen levels and often resolves the polycythemia without changing the target trough testosterone range 13.

Injection frequency adjustment. For men on biweekly intramuscular cypionate, splitting the same total dose into weekly injections reduces peak-to-trough swings. Lower peak testosterone levels produce less erythropoietic stimulation. Some clinicians use subcutaneous injection of smaller volumes every 3.5 days for the same reason.

Therapeutic phlebotomy. If dose adjustments do not bring hematocrit below 54% within 8 to 12 weeks, phlebotomy (removal of one unit, approximately 450 to 500 mL of whole blood) is the standard intervention. Each unit removed typically lowers hematocrit by 3 percentage points. The American Association of Clinical Endocrinology (AACE) 2020 position statement supports phlebotomy as a bridge measure while dose optimization continues 14.

Temporary cessation. The Endocrine Society guideline recommends stopping testosterone entirely if hematocrit exceeds 54% and restarting only after hematocrit returns below 50%. In practice, many clinicians use a lower restart threshold of 48% to provide additional margin 5.

Grapefruit and naringin supplementation. Some TRT clinics recommend naringin (a flavonoid found in grapefruit) as a natural approach to reducing hematocrit. A small in vitro study showed naringin inhibited erythroid colony formation, but no randomized controlled trial has confirmed a clinically meaningful hematocrit-lowering effect in humans 15. This remains an unproven adjunct.

How to Lower Hematocrit Without Stopping Treatment

For men whose hematocrit sits in the 50% to 53% range (elevated but below the 54% action threshold), lifestyle and protocol modifications can prevent it from climbing further.

Hydration is the simplest intervention. Drinking an additional 500 mL to 1 L of water daily expands plasma volume and dilutes the cellular fraction. The effect is modest (1 to 2 percentage points) but consistent 6.

Regular blood donation achieves the same physiologic effect as therapeutic phlebotomy. Donating whole blood every 8 weeks removes approximately 450 mL and typically lowers hematocrit by 3 points per donation. The American Red Cross allows donation every 56 days for men, which aligns well with TRT monitoring intervals. Men on TRT should confirm their donation eligibility with their local blood bank, as policies vary by region regarding donor medication use.

Treating underlying sleep apnea reduces the hypoxic drive for excess red blood cell production. A 2017 study found that CPAP adherence for 6 months reduced hematocrit by a mean of 1.8 percentage points in men with concurrent obstructive sleep apnea and TRT-induced polycythemia 16.

Smoking cessation removes the carbon monoxide stimulus for compensatory erythropoiesis. Iron restriction (avoiding iron supplements and limiting red meat intake) can slow red blood cell production, though this approach risks iron deficiency anemia if taken too far and should be monitored with ferritin levels.

Low Hematocrit: What It Means for Treatment Eligibility

A hematocrit below 38.3% in men or below 35.5% in women indicates anemia, which requires workup before hormone therapy begins. Low hematocrit can result from iron deficiency, chronic disease, kidney disease, bone marrow disorders, or acute blood loss.

The Endocrine Society guideline does not prohibit testosterone therapy in anemic men but requires that the cause of anemia be identified first 5. If the anemia is caused by hypogonadism itself (testosterone deficiency reduces erythropoiesis), TRT may be the treatment. The TTrials showed that testosterone therapy increased hemoglobin above 12.7 g/dL in 54% of anemic older men with unexplained anemia, compared to 15% in the placebo group 17.

For women on HRT, low hematocrit is less commonly a barrier to treatment initiation. Estradiol does not significantly stimulate erythropoiesis the way androgens do. However, anemia can worsen fatigue symptoms that overlap with menopausal complaints, making it important to distinguish hormonal fatigue from hematologic fatigue before attributing symptoms to estrogen deficiency.

GLP-1 receptor agonists like semaglutide and tirzepatide can indirectly affect hematocrit through rapid weight loss. Significant fat mass reduction alters plasma volume dynamics, and patients losing more than 10% of body weight may see transient hematocrit fluctuations in either direction. A post-hoc analysis of the STEP-1 trial (N=1,961) found no clinically significant mean hematocrit change at 68 weeks, but individual variation was notable in patients who lost more than 15% of body weight 18.

How to Raise Hematocrit When It Is Too Low

Raising a low hematocrit depends entirely on identifying the cause. The three most common correctable causes are iron deficiency, B12/folate deficiency, and chronic kidney disease with EPO insufficiency.

Iron deficiency anemia is the most prevalent cause worldwide, affecting approximately 1.2 billion people according to the WHO Global Burden of Disease data 19. Oral iron supplementation (ferrous sulfate 325 mg daily, providing 65 mg of elemental iron) raises hematocrit by approximately 1 percentage point per week in iron-deficient adults. Intravenous iron (ferric carboxymaltose, 750 mg infused twice over one week) works faster, with most patients seeing a 3 to 5 point hematocrit increase within 2 to 3 weeks 20.

B12 deficiency, particularly common in adults over 60 and in patients on metformin or proton pump inhibitors, responds to either oral supplementation (1 to 000 mcg daily) or intramuscular injections (1 to 000 mcg monthly). Folate deficiency corrects with 1 mg daily oral folic acid.

For men with low hematocrit caused by confirmed hypogonadism, testosterone therapy itself is the corrective intervention. The expected rise is 3 to 5 percentage points over the first 6 to 12 months, which is why baseline anemia due to testosterone deficiency is actually an indication for, not a contraindication to, TRT 9.

EPO-stimulating agents (darbepoetin alfa, epoetin alfa) are reserved for chronic kidney disease patients with hematocrit persistently below 30% despite iron repletion. These agents carry their own cardiovascular risks and are managed by nephrologists, not hormone therapy providers.

Monitoring Protocols: When and How Often to Check

The Endocrine Society guideline prescribes a clear monitoring cadence for men on TRT: check hematocrit at baseline, at 3 months after initiation or dose change, at 6 months, and then annually if stable 5. The AACE 2020 guideline adds that men with baseline hematocrit above 48% should be monitored more frequently, every 6 to 8 weeks during the first 6 months 14.

Dr. Abraham Morgentaler, associate clinical professor of urology at Harvard Medical School, has noted: "The biggest monitoring mistake I see in clinical practice is checking hematocrit only annually. The most dangerous period for polycythemia development is the first three to six months of therapy, and annual-only monitoring misses the window where intervention matters most" 21.

Timing of the blood draw matters. For men on intramuscular testosterone cypionate, hematocrit should be drawn at the midpoint or trough of the injection cycle, not at the peak. Drawing blood 2 to 3 days after a biweekly injection captures peak testosterone and peak erythropoietic stimulation, which may overestimate steady-state hematocrit.

For women on estradiol or progesterone HRT, routine hematocrit monitoring is not required by guidelines. Standard practice is to check CBC at baseline and then only if symptoms of anemia or polycythemia develop.

Patients on GLP-1 agonists do not require hematocrit-specific monitoring, but a CBC is often included in the metabolic panel drawn at 3-month and 6-month follow-ups. Any hematocrit value outside the reference range warrants further evaluation regardless of the treatment context.

A single elevated reading should never trigger a protocol change. Confirm with a second draw after 48 hours of adequate hydration. Two consecutive values above 54% constitute the action threshold per guideline consensus.